Global Information
회사소개 | 문의 | 비교리스트

Zynteglo : 신약 인사이트와 시장 예측(2030년)

Zynteglo- Drug Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 09월 상품 코드 959704
페이지 정보 영문 50 Pages
가격
US $ 2,750 ₩ 3,231,000 PDF (Single User License)
US $ 5,500 ₩ 6,463,000 PDF (Site License)
US $ 8,250 ₩ 9,695,000 PDF (Global License)


Zynteglo : 신약 인사이트와 시장 예측(2030년) Zynteglo- Drug Insight and Market Forecast - 2030
발행일 : 2020년 09월 페이지 정보 : 영문 50 Pages

Zynteglo 브랜드명으로 판매되고 있는 Betibeglogene autotemcel은 희귀하고 쇠약 가능성이 있는 혈액 질환의 일종인 베타지중해빈혈 치료제입니다. Bluebird Bio에 의해 개발되고, 2015년 2월에 미국식품의약국에 의해 획기적인 치료법의 지정을 받았습니다. 정기적인 혈액이 필요한 베타지중해빈혈 환자에 관한 2개 주요 연구에서 Zynteglo는 수혈 필요성을 줄이는데 효과적인 것으로 나타났습니다. 이러한 연구에서는 베타글로빈이 완전하게 결여되어 있지 않고, Zynteglo가 투여된 14명 환자 가운데 11명이 충분히 높은 수준의 적혈구를 가지고 있었기 때문에 치료후 적어도 1년간은 수혈을 필요로 하지 않았습니다.

베타지중해빈혈 치료제인 Zynteglo 시장 구조·동향에 대해 분석했으며, 제품 개요(용법·용량, 작용기서 등)과 관련 규제, 제품 개발·임상시험 진행 상황, 주요 7개국(미국, 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국), 일본) 시장 규모 동향 전망(2020-2030년), 시장 경쟁 상황·SWOT 분석, 기타 치료제와의 경쟁 상태, 자본 거래 동향, 향후 시장 성장 가능성 등을 조사·제시하고 있습니다.

목차

제1장 제품 개요

  • 증상
  • 작용기서
  • 용법·용량
    • 제형과 용량
  • 합성 경로
  • 약리학
    • 약력학
    • 약물동태
  • 부작용
  • 제품 현황
  • Zynteglo 개발 마일스톤
  • 출시 상세 동향
    • 미국
    • 유럽
    • 일본
  • 특허 상세 동향

제2장 SWOT 분석

  • 애널리스트의 견해

제3장 규제 마일스톤

  • 승인
  • 연구개발
  • 임상시험 정보
  • 안전성·유효성
  • 제품 개발 활동

제4장 시장 평가

  • 주요 7개국 시장 분석
  • 미국
  • 유럽
  • 일본
  • 주요 분석 결과

제5장 시장 진출 기업

제6장 새로운 치료법

제7장 부록

  • 보고서 구입 옵션
KSM 20.09.16

List of Tables

  • Table 1 Zynteglo, Description
  • Table 2 Zynteglo, Trial Diversification
  • Table 3 Zynteglo, Marketed Details United States
  • Table 4 Zynteglo, Marketed Details Europe
  • Table 5 Zynteglo, Marketed Details Japan
  • Table 6 Patent Details: Zynteglo
  • Table 7 Zynteglo, Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Zynteglo
  • Table 9 Zynteglo, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Zynteglo, US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Zynteglo, EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Zynteglo, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Zynteglo, Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Zynteglo
  • Figure 2 Patent Details, Zynteglo
  • Figure 3 Zynteglo, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Zynteglo, US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Zynteglo, EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Zynteglo, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Zynteglo, Japan Market Size from 2017 to 2030 (in Millions USD)

"Zynteglo- Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Zynteglo in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary:

Betibeglogene autotemcel, sold under the brand name Zynteglo, is a medication for the treatment for beta thalassemia, a rare and potentially debilitating blood disorder. It was developed by Bluebird Bio and was given breakthrough therapy designation by the U.S. Food and Drug Administration in February 2015. Zynteglo has been shown to be effective at reducing the need for blood transfusion in 2 main studies in patients with beta thalassaemia who required regular blood transfusions. In these studies, out of the 14 patients who did not completely lack beta-globin and were given Zynteglo, 11 of them had sufficiently high levels of red blood cells so that they did not need blood transfusions for at least 1 year after treatment.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Zynteglo.
  • The report contains historical and forecasted sales for Zynteglo till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Zynteglo.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Zynteglo Analytical Perspective by DelveInsight

  • In-depth Zynteglo Market Assessment

This report provides a detailed market assessment of Zynteglo in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Zynteglo Clinical Assessment

The report provides the clinical trials information of Zynteglo covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Zynteglo is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Zynteglo dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Zynteglo and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Zynteglo.
  • Our in-depth analysis of the sales data of Zynteglo from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Zynteglo in the market.

Key Questions:

  • What is the prescribed dosage and strengths of Zynteglo are available in the market?
  • What are the common adverse reactions or side effects of Zynteglo?
  • What is the product type, route of administration and mechanism of action of Zynteglo?
  • What are the chemical specifications of Zynteglo?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Zynteglo, and what is its future?
  • What are the marketed details of Zynteglo in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Zynteglo and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Zynteglo?
  • In which countries Zynteglo got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Zynteglo?
  • How the safety and efficacy results determined the approval of Zynteglo?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Zynteglo development?
  • What are the key designations that have been granted to Zynteglo?
  • What is the historical and forecasted market scenario of Zynteglo?
  • How is the market trend of Zynteglo is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Zynteglo?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Zynteglo
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options
Back to Top
전화 문의
F A Q